Moderna (NASDAQ:MRNA) Earns Neutral Rating from Analysts at Citigroup

Analysts at Citigroup started coverage on shares of Moderna (NASDAQ:MRNA) in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “neutral” rating and a $40.00 price target on the stock. Citigroup’s target price points to a potential upside of 14.25% from the stock’s current price.

A number of other research firms also recently commented on MRNA. Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Monday, November 18th. Evercore ISI set a $50.00 price target on Moderna in a research note on Friday, February 14th. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Finally, Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $59.60.

Moderna Stock Performance

MRNA opened at $35.01 on Thursday. The company’s 50-day simple moving average is $36.25 and its two-hundred day simple moving average is $48.01. Moderna has a 52-week low of $29.25 and a 52-week high of $170.47. The stock has a market capitalization of $13.51 billion, a P/E ratio of -3.77 and a beta of 1.86.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MRNA. FMR LLC raised its stake in shares of Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock valued at $776,075,000 after acquiring an additional 1,282,469 shares in the last quarter. State Street Corp raised its position in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Theleme Partners LLP raised its position in Moderna by 1.0% during the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock valued at $303,819,000 after purchasing an additional 72,028 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock worth $300,219,000 after buying an additional 171,774 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.